Navigation Links
GeNO LLC Initiates Phase 2 Trial For Nitric Oxide Delivery System

COCOA, Fla., Dec. 8, 2010 /PRNewswire/ -- GeNO LLC (, a privately held, advanced development-stage technology company, today announced commencement of the Phase 2 clinical trial for its stand-alone gas cylinder NITROSYL System. The initial indication to be studied for nitric oxide delivered via the GeNO NITROSYL System is as a diagnostic agent for administration as an adjunct to right heart catheterization in patients with Pulmonary Arterial Hypertension (WHO Group 1) to add information to improve clinical decision making. No agents are currently approved for this indication. Prior to conducting a Phase 3 registration study, GeNO LLC will first conduct this Phase 2, 10-patient pilot study to obtain preliminary safety and feasibility data from short term (15 minute) administration of inhaled nitric oxide via the GeNO Gas Cylinder NITROSYL System.  

GeNO's stand-alone gas cylinder stores premixed nitric oxide as nitrogen dioxide in either air or oxygen. The gas is allowed to flow through GeNO's proprietary cartridge containing ascorbic acid, which generates nitric oxide immediately prior to inhalation. A second cartridge is provided for redundancy

Leading researchers from four major medical centers will participate in the NITROSYL Phase 2 trial, including: Robert C. Bourge, M.D., Director, Division of Cardiovascular Disease at University of Alabama at Birmingham; Ioana Preston, M.D., Assistant Professor of Medicine at the Tufts University School of Medicine and the Co-Director for the Pulmonary Hypertension Center at Tufts Medical Center; Robert Schilz, D.O., Ph.D., Medical Director of Lung Transplant and Pulmonary Vascular Disease at UH Case Medical Center; and Fernando Torres, M.D., Associate Professor of Internal Medicine- Pulmonary and Critical Care at The University of Texas Southwestern Medical Center.

"As we move forward in our plans for these novel technologies, Phase 2 testing of the NITROSYL systems in patients is an important milestone for GeNO," said GeNO LLC Founder and President David Fine. "As a clinical-stage organization, this trial not only moves the in-hospital solution forward but also enables us to move our other exciting, patent-protected technologies, such as the GeNO Ambulatory NITROSYL System, towards clinical development as well."

Robert F. Roscigno, PhD, Vice President of GeNO, commented, "We believe that this System offers the potential to provide PAH patients, as well as the clinicians that treat them, with a safe and effective diagnostic agent. We look forward to seeing the results of this study, and also to filing additional INDs and completing acute and chronic treatment studies. There is a well-established body of clinical evidence suggesting clinical benefit on the use of inhaled nitric oxide for patients with a variety of serious diseases, and the GeNO NITROSYL Systems would add a valuable option for clinicians treating these difficult conditions.  GeNO's system would help address cost, complexity and the lack of portability of current treatment regimens and potentially reach a much larger group of patients."

The next version of GeNO's platform to enter the clinic later this year will be the GeNO Ambulatory NITROSYL System, which is a hand-held unit with a disposable liquid source.  This portable unit snaps into a small, battery operated pump module attaching to a hip or arm holster and provides up to a 4-day continuous supply of inhaled nitric oxide for chronic use.  The simplicity and ease-of-use this system has the potential to greatly expand the use of inhaled nitric oxide to many new chronic indications.  


GeNO LLC, founded in 2006, is a privately held, advanced development-stage technology company that is developing innovative nitric oxide (NO) generation and delivery platforms to enable the broad potential of inhaled nitric oxide to be realized. The company is focused on applying the new technology to deliver inhaled nitric oxide to patients in a wide variety of settings, including ambulatory and in-home use for potential chronic treatment. GeNO's NITROSYL  Systems will be regulated by the FDA as new drugs with their own NDAs. GeNO plans to submit a second IND application to FDA later this year to begin evaluation of the GeNO Ambulatory NITROSYL System. The company has five US patents with additional patent applications pending. Media Contacts: Carla Burigatto, 610-457-2178  Brian Heffron, 781-799-9568

Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

2. Circassia Initiates Phase II Trials of Novel Grass and Ragweed Allergy Therapies and Advances Phase III Plans for cat Allergy T-Cell Vaccine
3. Cylene Initiates Phase I Trial in Multiple Myeloma With CX-4945 Inhibitor of CK2 and Closes Accompanying Financing
4. Xenon Pharmaceuticals Initiates a Phase 2 Clinical Trial in Post Herpetic Neuralgia (PHN) for Topical XEN402.
5. Pieris Initiates Phase I Clinical Trial for Lead Anticalin Compound
6. Onyx Pharmaceuticals Initiates Phase 1 Study of Oral Proteasome Inhibitor in Advanced Solid Tumors
7. NewLink Initiates Pivotal Phase 3 Clinical Trial of HyperAcute(R)-Pancreas Immunotherapy for Resected Pancreatic Cancer
8. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1/2 Combination Study of MM-111 and Herceptin in Patients with Advanced Her2 Positive Breast Cancer
9. Fibrocell Science, Inc. Initiates Histology Study of azficel-T
10. Chimerix Initiates Phase 1 Study of CMX157
11. Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent AF
Post Your Comments:
(Date:11/24/2015)... -- SHPG ) announced today that Jeff Poulton ... th Annual Healthcare Conference in New York City ... EST (1:30 p.m. GMT). --> SHPG ) announced today ... the Piper Jaffray 27 th Annual Healthcare Conference in ... 2015, at 8:30 a.m. EST (1:30 p.m. GMT). --> ...
(Date:11/24/2015)... Ltd. (OTCQB: TIKRF) today announced that its Annual General Meeting of Shareholders ... Israel time, at the law offices of Goldfarb Seligman ... Floor, Tel Aviv, Israel . ... to the Board of Directors; , election of Liat ... an amendment to certain terms of options granted to our Chief Executive ...
(Date:11/24/2015)... , Nov. 24, 2015  Twist Bioscience, ... that Emily Leproust, Ph.D., Twist Bioscience chief executive ... Healthcare Conference on December 1, 2015 at 3:10 ... in New York City. --> ... . Twist Bioscience is on Twitter. Sign ...
(Date:11/24/2015)... ... November 24, 2015 , ... InSphero AG, the leading ... culture models, has promoted Melanie Aregger to serve as Chief Operating Officer. ... on the management team and was promoted to Head of InSphero Diagnostics ...
Breaking Biology Technology:
(Date:11/11/2015)... Minn. , Nov. 11, 2015   MedNet Solutions ... entire spectrum of clinical research, is pleased to announce that ... in Clinical Trials (PCT) event, to be held November ... be able to view live demonstrations of iMedNet ... and learn how iMedNet has been able to ...
(Date:11/9/2015)... 9, 2015  Synaptics Inc. (NASDAQ: SYNA ), ... broader entry into the automotive market with a comprehensive ... pace of consumer electronics human interface innovation. Synaptics, industry-leading ... for the automotive industry and will be implemented in ... Europe , Japan , and ...
(Date:10/29/2015)... 29, 2015  The J. Craig Venter Institute (JCVI) ... Synthesis and Biosecurity: Lessons Learned and Options for the ... and Human Services guidance for synthetic biology providers has ... --> --> Synthetic biology ... potential to pose unique biosecurity threats. It now is ...
Breaking Biology News(10 mins):